Can you make money from worms? Divergence, a small biotechnology company in St. Louis, thinks it can. The company is using genomics approaches — including RNA interference — to develop highly specific chemicals and drugs against parasitic nematodes.
The market for such improved nematicides could reach several billion dollars, according to Divergence president and CEO James McCarter. It would include nematicides to protect plants, transgenic plants that make their own worm toxins, and anti-nematode drugs for animals.